Dogwood Therapeutics, Inc. (DWTX)
NASDAQ: DWTX · Real-Time Price · USD
1.400
-0.010 (-0.71%)
At close: Oct 9, 2026, 4:00 PM EDT
1.450
+0.050 (3.57%)
After-hours: Oct 9, 2026, 7:30 PM EDT
Dogwood Therapeutics Employees
Dogwood Therapeutics had 8 employees as of December 31, 2025. The number of employees decreased by 4 or -33.33% compared to the previous year. That makes Dogwood Therapeutics the 40,669th largest employer in the world and 6,174th in the United States.
Employees
8
Change (1Y)
-4
Growth (1Y)
-33.33%
Revenue / Employee
n/a
Profits / Employee
-$4,505,161
Market Cap
47.59M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 8 | -4 | -33.33% |
| Dec 31, 2024 | 12 | 8 | 200.00% |
| Dec 31, 2023 | 4 | 0 | - |
| Dec 31, 2022 | 4 | -1 | -20.00% |
| Dec 31, 2021 | 5 | 2 | 66.67% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Celularity | 115 |
| Elicio Therapeutics | 33 |
| eXoZymes | 32 |
| INmune Bio | 21 |
| ImageneBio | 18 |
| Edesa Biotech | 17 |
| Instil Bio | 17 |
| Serina Therapeutics | 16 |
DWTX News
- 3 days ago - Dogwood to Participate in the 2026 Maxim Growth Summit - GlobeNewsWire
- 25 days ago - Dogwood completes patient enrollment in Halneuron trial - TheFly
- 25 days ago - Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial - GlobeNewsWire
- 4 weeks ago - Dogwood Therapeutics Slides: Corporate presentation - Filings
- 5 weeks ago - Dogwood Therapeutics Transcript: KOL event - Transcripts
- 5 weeks ago - Dogwood Therapeutics Slides: KOL event - Filings
- 7 weeks ago - Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026 - GlobeNewsWire
- 1 month ago - Dogwood Therapeutics Announces Second Quarter 2026 Financial Results - GlobeNewsWire